Skip to main content
SpringerLink
Log in

Prognosis of Hepatocellular Carcinoma Among Cancer Survivors with Other Types of Primary Tumors

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The clinical characteristics and outcomes of secondary hepatocellular carcinoma (HCC) in cancer survivors with other prior malignancies remain poorly understood. We aimed to depict the features of HCC patients with other prior cancer and to examine the prognostic effect of prior cancer in those patients.

Methods

All patients diagnosed with HCC between 2004 and 2014 were identified from the Surveillance, Epidemiology, and End Results database. Kaplan–Meier curves and Cox regression analysis were conducted to determine survival differences and impact of prior cancer history.

Results

In total, 32,343 eligible patients with HCC were included in the current study, and 2830 (8.7%) of those patients had prior cancer. Patients who had prior cancer were older and more frequently at localized or regional stages of HCC compared to those without a history of cancer. No differences in overall or cancer-specific survival rates were observed among patients with or without prior cancer, as revealed by the Kaplan–Meier curves. In multivariable Cox regression analysis, a history of cancer was not a prognostic factor for worse overall (HR = 0.99, 95%CI 0.94–1.03, P = 0.577) or HCC-specific (HR = 1.01, 95%CI 0.96–1.06, P = 0.802) survival after adjustment for various covariates.

Conclusions

Subsequent HCC in cancer survivors has several different clinical characteristics compared with primary HCC. A history of prior cancer did not significantly contribute to a worse prognosis for subsequent HCC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA A Cancer J Clin. 2018;68:7–30.

    Article  Google Scholar 

  2. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485–1491.

    Article  Google Scholar 

  3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.

    Article  CAS  Google Scholar 

  4. Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66:271–289.

    Article  Google Scholar 

  5. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271.

    Article  Google Scholar 

  6. Chien SH, Liu CJ, Hong YC, et al. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study. J Cancer Res Clin Oncol. 2015;141:1995–2004.

    Article  CAS  Google Scholar 

  7. Chien SH, Liu CJ, Hu YW, et al. Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: a nationwide population-based study. Int J Cancer. 2015;137:658–665.

    Article  CAS  Google Scholar 

  8. Sun L-C, Tai Y-Y, Liao S-M, et al. Clinical characteristics of second primary cancer in colorectal cancer patients: the impact of colorectal cancer or other second cancer occurring first. World J Surg Oncol. 2014;12:73.

    Article  Google Scholar 

  9. Baras N, Dahm S, Haberland J, et al. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990–2012). Br J Haematol. 2017;177:226–242.

    Article  Google Scholar 

  10. Murphy CC, Gerber DE, Pruitt SL. Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the surveillance, epidemiology, and end results program. JAMA Oncol. 2018;4:832–836. https://doi.org/10.1001/jamaoncol.2017.3605.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Pruitt SL, Laccetti AL, Xuan L, Halm EA, Gerber DE. Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. Br J Cancer. 2017;116:717–725.

    Article  Google Scholar 

  12. Laccetti AL, Pruitt SL, Xuan L, Halm EA, DE Gerber. Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. J Natl Cancer Inst. 2015;107. https://doi.org/10.1093/jnci/djv002.

  13. Li QG, Gan L, Liang L, Li XX, Cai SJ. The influence of marital status on stage at diagnosis and survival of patients with colorectal cancer. Oncotarget. 2015;6:7339–7347.

    Article  Google Scholar 

  14. Dinh KT, Mahal BA, Ziehr DR, et al. Risk of prostate cancer mortality in men with a history of prior cancer. BJU Int. 2016;117:E20–E28.

    Article  Google Scholar 

  15. Laccetti AL, Pruitt SL, Xuan L, Halm EA, Gerber DE. Prior cancer does not adversely affect survival in locally advanced lung cancer: a national SEER-medicare analysis. Lung Cancer (Amsterdam, Netherlands). 2016;98:106–113.

    Article  Google Scholar 

  16. Sadler C, Goldfarb M. Comparison of primary and secondary breast cancers in adolescents and young adults. Cancer. 2015;121:1295–1302.

    Article  Google Scholar 

  17. Smyth EC, Tarazona N, Peckitt C, et al. Exclusion of gastrointestinal cancer patients with prior cancer from clinical trials: is this justified? Clin Colorectal Cancer. 2016;15:e53–e59.

    Article  Google Scholar 

  18. Varty PP, Delrio P, Boulos PB. Survival in colorectal carcinoma associated with previous extracolonic cancer. Ann R Coll Surg Engl. 1994;76:180–184.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Pandurengan RK, Dumont AG, Araujo DM, et al. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol Off J Eur Soc Med Oncol. 2010;21:2107–2111.

    Article  CAS  Google Scholar 

  20. Pulte D, Gondos A, Brenner H. Long-term survival of patients diagnosed with non-Hodgkin lymphoma after a previous malignancy. Leuk Lymphoma. 2009;50:179–186.

    Article  Google Scholar 

  21. Lopez-Encuentra A, Gomez de la Camara A, Rami-Porta R, Duque-Medina JL, de Nicolas JL, Sayas J. Previous tumour as a prognostic factor in stage I non-small cell lung cancer. Thorax. 2007;62:386–390.

    Article  Google Scholar 

  22. Kanematsu M, Imaeda T, Yamawaki Y, et al. Hepatocellular carcinoma with extrahepatic primary neoplasms. Gastrointest Radiol. 1992;17:53–57.

    Article  CAS  Google Scholar 

  23. Zeng QA, Qiu J, Zou R, et al. Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: a long-term follow-up study. BMC Cancer. 2012;12:148.

    Article  Google Scholar 

  24. Fernández-Ruiz M, Guerra-Vales J-M, Castelbón-Fernández F-J, Llenas-García J, Caurcel-Díaz L, Colina-Ruizdelgado F. Multiple primary malignancies in Spanish patients with hepatocellular carcinoma: analysis of a hospital-based tumor registry. J Gastroenterol Hepatol. 2009;24:1424–1430.

    Article  Google Scholar 

  25. Xu W, Liao W, Ge P, et al. Multiple primary malignancies in patients with hepatocellular carcinoma: a largest series with 26-year follow-up. Medicine. 2016;95:e3491.

    Article  Google Scholar 

  26. Gerber DE, Laccetti AL, Xuan L, Halm EA and Pruitt SL. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst. 2014;106. https://doi.org/10.1093/jnci/dju302.

  27. Kim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of clinical oncology and friends of cancer research joint research statement. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:3737–3744.

    Article  CAS  Google Scholar 

  28. Zhao GS, Liu Y, Zhang Q, et al. Transarterial chemoembolization combined with Huaier granule for the treatment of primary hepatic carcinoma: safety and efficacy. Medicine. 2017;96:e7589.

    Article  Google Scholar 

  29. Santoro A, Rimassa L, Borbath I, et al. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol. 2013;14:55–63.

    Article  CAS  Google Scholar 

  30. Kasuya G, Kato H, Yasuda S, et al. Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma: combined analyses of 2 prospective trials. Cancer. 2017;123:3955–3965.

    Article  CAS  Google Scholar 

  31. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

The authors acknowledge the efforts of the SEER Program cancer registries in the creation of the SEER database.

Funding

This work was funded by the Key Program of the National Natural Science Foundation of China (No.81330011) and the Science Fund for Creative Research Groups of the National Natural Science Foundation of China (No. 81721091).

Author information

Author notes

  1. Xiaoyuan Bian and Xingkang He have contributed equally to this work.

Authors and Affiliations

  1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, 310003, Hangzhou, People’s Republic of China

    Xiaoyuan Bian, Liya Yang, Wenrui Wu & Lanjuan Li

  2. Collaborative Innovation Centre for Diagnosis and Treatment of Infectious Diseases, Hangzhou, People’s Republic of China

    Xiaoyuan Bian, Liya Yang, Wenrui Wu & Lanjuan Li

  3. Department of Gastroenterology, Sir Run Run Shaw Hospital, Zhejiang University Medical School, Hangzhou, 310016, People’s Republic of China

    Xingkang He

  4. Department of Microbiology, Tumor and Cell Biology, Karolinska Institute, 171 77, Stockholm, Sweden

    Xingkang He

Authors
  1. Xiaoyuan Bian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xingkang He
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liya Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wenrui Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lanjuan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

XB, XH: Designed experiments, LY, WW: data analysis and XB, LL: wrote the manuscript text. All authors reviewed the manuscript.

Corresponding author

Correspondence to Lanjuan Li.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bian, X., He, X., Yang, L. et al. Prognosis of Hepatocellular Carcinoma Among Cancer Survivors with Other Types of Primary Tumors. Dig Dis Sci 65, 2140–2147 (2020). https://doi.org/10.1007/s10620-019-05917-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05917-8

Keywords

Search

Navigation